

Organ-on-a-chip and organoids to model the cardiac pathophysiology

Albano C. Meli, Ph.D.
CRCN Inserm
albano.meli@inserm.fr

What are stem cells?

What is a stem cell?

A single cell that can




Image prepared by Catherine Twomey for the National Academies, *Understanding Stem Cells: An Overview of the Science and Issues* from the National Academies, <http://www.nationalacademies.org/stemcells>. Academic noncommercial use is permitted.

Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors

Kazutoshi Takahashi¹ and Shinya Yamanaka^{1,2,*}

¹Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan

²CREST, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan

*Contact: yamanaka

DOI 10.1016/j.cell.



Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors

Kazutoshi Takahashi,¹ Koji Tanabe,¹ Mari Ohnuki,¹ Megumi Narita,^{1,2} Tomoko Ichisaka,^{1,2} Kiichiro Tomoda,³ and Shinya Yamanaka^{1,2,3,4,*}

¹Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan


²CREST, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan

³Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA

⁴Institute for Integrated Cell-Material Sciences, Kyoto University, Kyoto 606-8507, Japan


*Correspondence: yamanaka@frontier.kyoto-u.ac.jp

DOI 10.1016/j.cell.2007.11.019




Reprogramming factors

iPS reprogramming has...



... no ethical issue compared to hES cells!

Human iPS cell derivation, differentiation and applications




Differentiation of hiPSC in cardiomyocytes



conditions and assumptions:

- ✓ Differentiation of specific populations of CMs (ventricular vs atrial vs nodal)
- ✓ Purified cardiac population
- ✓ Obtain mature (adult) hiPSC-CMs

Current methods for cardiac differentiation of hPSC



Monolayer-based cardiac differentiation protocol




Adapted from Moreau *et al.*, 2017
Sleiman *et al.*, 2020

SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells


Nicole C Dubois¹, April M Craft¹, Parveen Sharma², David A Elliott³, Edouard G Stanley³, Andrew G Elefanty³, Anthony Gramolini² & Gordon Keller¹

To identify cell-surface markers specific to human cardiomyocytes, we screened cardiovascular cell populations derived from human embryonic stem cells (hESCs) against a panel of 370 known CD antibodies. This screen identified the signal-regulatory protein alpha (SIRPA) as a marker expressed specifically on cardiomyocytes derived from hESCs and human induced pluripotent stem cells (hiPSCs), and PECAM, THY1, PDGFRB and ITGA1 as markers of the nonmyocyte population. Cell sorting with an antibody against SIRPA allowed for the enrichment of cardiac precursors and cardiomyocytes from hESC/hiPSC differentiation cultures, yielding populations of up to 98% cardiac troponin T-positive cells. When plated in culture, SIRPA-positive cells were contracting and could be maintained over extended periods of time. These findings provide a simple method for isolating populations of cardiomyocytes from human pluripotent stem cell cultures, and thereby establish a readily adaptable technology for generating large numbers of enriched cardiomyocytes for therapeutic applications.

Purified beating syncytium from hPSC-CMs



NKX2-5-GFP
embryoid
bodies



SIRPA⁺- cell derived
population

Metabolic sorting of hPSC-CMs

Cell Stem Cell
Resource



Distinct Metabolic Flow Enables Large-Scale Purification of Mouse and Human Pluripotent Stem Cell-Derived Cardiomyocytes

Shugo Tohyama,^{1,3} Fumiyuki Hattori,^{1,4,*} Motoaki Sano,¹ Takako Hishiki,² Yoshiko Nagahata,^{2,5} Tomomi Matsuura,^{2,5} Hisayuki Hashimoto,¹ Tomoyuki Suzuki,⁶ Hiromi Yamashita,^{1,4} Yusuke Satoh,¹ Toru Egashira,¹ Tomohisa Seki,¹ Naoto Muraoka,¹ Hiroyuki Yamakawa,¹ Yasuyuki Ohgino,¹ Tomofumi Tanaka,⁴ Masatoshi Yoichi,⁴ Shinsuke Yuasa,¹ Mitsushige Murata,¹ Makoto Suematsu,^{2,5} and Keiichi Fukuda^{1,*}

¹Department of Cardiology

²Department of Biochemistry

Keio University School of Medicine, Tokyo 160-8582, Japan

³Japan Society for the Promotion of Science, Tokyo 102-8472, Japan

⁴Asubio Pharma, Kobe 650-0047, Japan


⁵Japan Science and Technology Agency (JST), Exploratory Research for Advanced Technology (ERATO) Suematsu Gas Biology Project, Tokyo 160-8582, Japan

⁶Department of Cardiovascular Research, Research Institute of Environmental Medicine, Nagoya University, Nagoya 464-8601, Japan







*Correspondence: hattori.fumiyuki.ef@asubio.co.jp (F.H.), kfukuda@a2.keio.jp (K.F.)

<http://dx.doi.org/10.1016/j.stem.2012.09.013>


Metabolic sorting of hPSC-CMs



How mature are hPSC-derived CMs in the dish?



Comparison of action potentials



hiPSC-CMs exhibit spontaneous automaticity!



European Heart Journal
doi:10.1093/eurheartj/ehs096


BASIC SCIENCE

Derivation and cardiomyocyte differentiation of induced pluripotent stem cells from heart failure patients

**Limor Zwi-Dantsis^{1,2}, Irit Huber¹, Manhal Habib¹, Aaron Winterstern¹,
Amira Gepstein¹, Gil Arbel¹, and Lior Gepstein^{1,3*}**


¹Sohnis Research Laboratory for Cardiac Electrophysiology and Regenerative Medicine, The Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, POB 9649, Haifa 31096, Israel; ²Biotechnology Interdisciplinary Unit, Technion–Israel Institute of Technology, Haifa, Israel; and ³Cardiology Department, Rambam Medical Center, Haifa, Israel

Integration of HF hiPSC-CM in host cardiac tissue



Integrated hiPSC-CMs with rat CMs


Integration of HF hiPSC-CM in host cardiac tissue




Integrated hiPSC-CMs with rat CMs


**How to improve the maturity of
hiPSC-derived cardiomyocytes?**

Stem cell maturation



Developmental progression of cardiac myocytes






Cell Reports

Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes

Graphical Abstract



Authors

Dries A.M. Feyen, Wesley L. McKeithan, Arne A.N. Bruyneel, ..., Thomas Eschenhagen, Christian M. Metallo, Mark Mercola

Correspondence

mmercola@stanford.edu

In Brief


Physiological immaturity of iPSC-derived cardiomyocytes limits their fidelity as disease models. Feyen et al. developed a low glucose, high oxidative substrate media that increase maturation of ventricular-like hiPSC-CMs in 2D and 3D cultures relative to standard protocols. Improved characteristics include a low resting V_m , rapid depolarization, and increased Ca^{2+} dependence and force generation.

Highlights



- We developed a defined maturation medium for hiPSC-CMs
- The media improve electrophysiological and mechanical characteristics of hiPSC-CMs
- The media improve the fidelity of disease modeling


Fatty acids improve the hPSC-CMs

A






F






Biocompatible polyethylene glycol (PEG) hydrogel arrays imitating the myocardial ECM and allowing formation of engineered cardiac tissue constructs.

Monolayer



Monolayer






Brief UltraRapid Communication

Matrigel Mattress



A Method for the Generation of Single Contracting Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Tromondae K. Feaster, Adrian G. Cadar, Lili Wang, Charles H. Williams, Young Wook Chun, Jonathan E. Hempel, Nathaniel Bloodworth, W. David Merryman, Chee Chew Lim, Joseph C. Wu, Björn C. Knollmann, Charles C. Hong


Matrigel mattress





Matrigel mattress




Matrigel mattress



Matrigel mattress



Engineered heart tissues






Figure 2. Histological Evaluation of hiPSC-EHTs

(A) Representative still view of a living EHT. (B) Longitudinal section stained with H&E. (C) Cross section stained for dystrophin. (D) Longitudinal section stained for MLC2v. (E) Whole-mount immunofluorescence confocal microscopic section of EHT stained with DRAQ5 (nuclei, blue) and α -actinin (green). (F) Confocal analysis of hiPSC-CM cultured in 2D for 30 days stained with DRAQ5 (blue) and antibodies against cardiac MLC2v (red) and α -actinin (green). (G and H) Whole-mount immunofluorescence confocal microscopic section of 30- to 35-day-old EHTs stained with DRAQ5 (blue) and antibodies against α -actinin (red; G) and caveolin-3 (green; G) or phalloidin (red; H) and an antibody against junctophilin-2 (green; H). (I) Transmission electron microscopy of 35-day-old EHT. Arrows indicate structures resembling t tubules. See also [Figure S2](#).




Figure 2. Histological Evaluation of hiPSC-EHTs

(A) Representative still view of a living EHT. (B) Longitudinal section stained with H&E. (C) Cross section stained for dystrophin. (D) Longitudinal section stained for MLC2v. (E) Whole-mount immunofluorescence confocal microscopic section of EHT stained with DRAQ5 (nuclei, blue) and α -actinin (green). (F) Confocal analysis of hiPSC-CM cultured in 2D for 30 days stained with DRAQ5 (blue) and antibodies against cardiac MLC2v (red) and α -actinin (green). (G and H) Whole-mount immunofluorescence confocal microscopic section of 30- to 35-day-old EHTs stained with DRAQ5 (blue) and antibodies against α -actinin (red; G) and caveolin-3 (green; G) or phalloidin (red; H) and an antibody against junctophilin-2 (green; H). (I) Transmission electron microscopy of 35-day-old EHT. Arrows indicate structures resembling t tubules. See also [Figure S2](#).




Figure 5. Regulation of Contractile Function of hiPSC-EHTs by Inotropic Drugs

Average contraction peaks before (black) and after (red) the respective inotropic drug intervention.

(A–H) Positive inotropic drugs (A–F) were tested at submaximal (0.5–0.6 mM), and negative inotropic drugs (G and H) at high (1.8 mM; H) and submaximal (0.5 mM; G) calcium concentrations. Depicted is the electrically stimulated (1.5–2 Hz) mean relative force in percentage of baseline maximum \pm SEM in modified Tyrode's solution; replicates are indicated as EHTs/number of independent experiments. (A) calcium (5 mM; $n = 8/2$). (B) ouabain (100 nM; $n = 6/2$). (C) Bay K-8644 (300 nM; $n = 4/1$). (D) EMD-57033 (10 μ M; $n = 4/1$). (E) isoprenaline (100 nM; $n = 4/1$). (F) rolipram (10 μ M) + isoprenaline (100 nM, red) versus isoprenaline (100 nM, black; $n = 11/2$). (G) ryanodine (0.3 μ M, red; 10 μ M, blue; $n = 6/2$). (H) verapamil (1 μ M; $n = 18/2$).

See also [Figure S5](#).


LETTER

<https://doi.org/10.1038/s41586-018-0016-3>


Advanced maturation of human cardiac tissue grown from pluripotent stem cells

Kacey Ronaldson-Bouchard¹, Stephen P. Ma¹, Keith Yeager¹, Timothy Chen¹, LouJin Song², Dario Sirabella¹, Kumi Morikawa², Diogo Teles^{1,3,4}, Masayuki Yazawa² & Gordana Vunjak-Novakovic^{1,5*}

Early-stage intensity-trained tissues




Early-stage intensity-trained tissues



Early- vs late-stage intensity-trained tissues

Early-stage intensity-trained tissues




Late-stage intensity-trained tissues




An organ-on-a-chip model for pre-clinical drug evaluation in progressive non-genetic cardiomyopathy

Erika Yan Wang^a, Uros Kuzmanov^{b,c}, Jacob B. Smith^d, Wenkun Dou^e, Naimeh Rafatian^f, Benjamin Fook Lun Lai^a, Rick Xing Ze Lu^a, Qinghua Wu^a, Joshua Yazbeck^a, Xiao-Ou Zhang^g, Yu Sun^e, Anthony Gramolini^{b,c}, Milica Radisic^{a,d,f,*}


A




B




A




C



B




D




One-way repeated measures ANOVA over time (p-value)				
Comparison	48 hrs-day 0	week 1-day 0	week 2-day 0	week 3-day 0
CTRL	NS	0.0461	0.0261	0.0271
Ang II	0.0027	0.013	NS	NS

E














One-way repeated measures ANOVA over time (p-value)				
Comparison	48 hrs-day 0	week 1-day 0	week 2-day 0	week 3-day 0
CTRL	NS	NS	NS	0.0429
Ang II	0.0366	0.0096	0.0004	0.0014

F




One-way repeated measures ANOVA over time (p-value)				
Comparison	48 hrs-day 0	week 1-day 0	week 2-day 0	week 3-day 0
CTRL	NS	NS	0.0017	0.0001
Ang II	NS	NS	NS	0.0065


A**B****C**

D**F****H****E****G****I**


A Collagen/autofluorescence




B




C



D



E



F

